Welcome to our dedicated page for Cartesian SEC filings (Ticker: RNAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cartesian Therapeutics, Inc. filings document the regulatory disclosures of a late clinical-stage biotechnology company developing cell therapy candidates for autoimmune diseases. Recent Form 8-K reports furnish quarterly and annual financial results, business updates, corporate slide presentations, and clinical disclosures for Descartes-08, including autoimmune indications such as generalized myasthenia gravis, myositis, juvenile dermatomyositis and systemic lupus erythematosus.
Proxy materials cover director elections, board committee service, executive compensation, equity awards and other governance matters. Additional 8-K filings report board changes and compensatory arrangements, while the company's disclosures also describe cash resources, FDA designations, forward-looking statements and equity incentive activity tied to its common stock.
Cartesian Therapeutics, Inc. reported that its Board of Directors appointed June Seymour as Chief Accounting Officer, effective October 27, 2025. She brings over 20 years of financial leadership in life sciences, including senior finance roles at DNAnexus, Neogene Therapeutics, Autolus and earlier experience at Ernst & Young.
Under her employment agreement, Ms. Seymour will receive an annual base salary of $385,000 and will be eligible for an annual performance bonus targeted at 35% of base salary, prorated for 2025. If her employment is terminated without cause or she resigns for good reason, she may receive six months of salary continuation, a pro-rated bonus and up to six months of COBRA premium payments, subject to customary release and restrictive covenants.
Ms. Seymour will also receive a $80,000 sign-on bonus and an option to purchase 50,000 shares of common stock at the closing price on the October 27, 2025 grant date. The option vests over four years, with 25% after 12 months and the remainder in three equal annual installments. She is subject to non-compete and non-solicitation covenants, and has signed the company’s standard executive indemnification agreement. The company’s Chief Financial Officer, Blaine Davis, remains the principal financial and principal accounting officer.